432 related articles for article (PubMed ID: 15266218)
1. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
2. MDR- and CYP3A4-mediated drug-herbal interactions.
Pal D; Mitra AK
Life Sci; 2006 Mar; 78(18):2131-45. PubMed ID: 16442130
[TBL] [Abstract][Full Text] [Related]
3. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?
Gutmann H; Poller B; Büter KB; Pfrunder A; Schaffner W; Drewe J
Planta Med; 2006 Jun; 72(8):685-90. PubMed ID: 16755466
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Eagling VA; Profit L; Back DJ
Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
[TBL] [Abstract][Full Text] [Related]
5. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
Patel J; Hussain A; Pal D; Mitra AK
Am J Ther; 2004; 11(2):114-23. PubMed ID: 14999363
[TBL] [Abstract][Full Text] [Related]
6. Herbal modulation of P-glycoprotein.
Zhou S; Lim LY; Chowbay B
Drug Metab Rev; 2004 Feb; 36(1):57-104. PubMed ID: 15072439
[TBL] [Abstract][Full Text] [Related]
7. Transfected MDCK cell line with enhanced expression of CYP3A4 and P-glycoprotein as a model to study their role in drug transport and metabolism.
Kwatra D; Budda B; Vadlapudi AD; Vadlapatla RK; Pal D; Mitra AK
Mol Pharm; 2012 Jul; 9(7):1877-86. PubMed ID: 22676443
[TBL] [Abstract][Full Text] [Related]
8. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
9. CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies.
Engman HA; Lennernäs H; Taipalensuu J; Otter C; Leidvik B; Artursson P
J Pharm Sci; 2001 Nov; 90(11):1736-51. PubMed ID: 11745731
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo.
Shi J; Cao B; Zha WB; Wu XL; Liu LS; Xiao WJ; Gu RR; Sun RB; Yu XY; Zheng T; Li MJ; Wang XW; Zhou J; Mao Y; Ge C; Ma T; Xia WJ; Aa JY; Wang GJ; Liu CX
Acta Pharmacol Sin; 2013 Oct; 34(10):1349-58. PubMed ID: 23892274
[TBL] [Abstract][Full Text] [Related]
11. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products.
Budzinski JW; Trudeau VL; Drouin CE; Panahi M; Arnason JT; Foster BC
Can J Physiol Pharmacol; 2007 Sep; 85(9):966-78. PubMed ID: 18066144
[TBL] [Abstract][Full Text] [Related]
12. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
Berginc K; Trdan T; Trontelj J; Kristl A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp.
Li X; Hu J; Wang B; Sheng L; Liu Z; Yang S; Li Y
Toxicol Appl Pharmacol; 2014 Mar; 275(2):163-75. PubMed ID: 24380838
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
15. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.
Dürr D; Stieger B; Kullak-Ublick GA; Rentsch KM; Steinert HC; Meier PJ; Fattinger K
Clin Pharmacol Ther; 2000 Dec; 68(6):598-604. PubMed ID: 11180019
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
17. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
18. Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir.
Luo S; Wang Z; Patel M; Khurana V; Zhu X; Pal D; Mitra AK
Int J Pharm; 2011 Jul; 414(1-2):77-85. PubMed ID: 21571053
[TBL] [Abstract][Full Text] [Related]
19. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
20. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin.
Wang EJ; Barecki-Roach M; Johnson WW
J Pharm Pharmacol; 2004 Jan; 56(1):123-8. PubMed ID: 14980009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]